Update on community-acquired pneumonia. New pathogens and new concepts in treatment.
Recent years have witnessed the emergence of new pathogens linked to community-acquired pneumonia (CAP) along with new antibiotics designed to combat them. In this article, Dr Mandell presents an expert's view on these developments in the context of treatment guidelines for CAP. He also explores monotherapy versus combination therapy, the efficacy of rapid initiation of treatment, and short-course therapy as a hedge against antimicrobial resistance.
Mandell
Lionel A
LA
Division of Infectious Diseases, McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada. lmandell@mcmaster.ca
D000890:Anti-Infective Agents / Q000008:administration & dosage*; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000382:microbiology; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D029121:Metapneumovirus; D016106:Methicillin Resistance; D011014:Pneumonia / Q000188:drug therapy* / Q000382:microbiology*; D045473:Severe acute respiratory syndrome-related coronavirus; D013211:Staphylococcus aureus
D000890:Anti-Infective Agents